
Quest Diagnostics Incorporated: shareholders and insiders
Price
$259.69
November 18, 2026Market cap $28.5B
What Ploutos Investor adds for Quest Diagnostics
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 19, 2025 to Nov 16, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$47M
9 people
From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan98%
- The rest2%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $37M by 8 people
- 2025: no buys, sold $11M by 2 people
- 2026: no buys, sold $37M by 8 people
- Nov 13, 2026Michael J DeppeSVP, Corp. Controller & CAOKind10b5-1
- Nov 13, 2026Michael J DeppeSVP, Corp. Controller & CAOKind10b5-1
- Nov 13, 2026Michael J DeppeSVP, Corp. Controller & CAOKind10b5-1
- Nov 13, 2026Michael J DeppeSVP, Corp. Controller & CAOKind10b5-1
- Nov 9, 2026Patrick PlewmanSVP for Diagnostic ServicesKind10b5-1
- Nov 9, 2026Patrick PlewmanSVP for Diagnostic ServicesKind10b5-1
- Nov 9, 2026Patrick PlewmanSVP for Diagnostic ServicesKind10b5-1
- Nov 9, 2026Patrick PlewmanSVP for Diagnostic ServicesKind10b5-1
- Nov 9, 2026Patrick PlewmanSVP for Diagnostic ServicesKind10b5-1
- Nov 3, 2026Subu RamachandranSVP, Regional BusinessesKind
- Nov 3, 2026Catherine T. DohertyExecutive Vice PresidentKind10b5-1
- Nov 3, 2026Catherine T. DohertyExecutive Vice PresidentKind10b5-1
- Nov 3, 2026Catherine T. DohertyExecutive Vice PresidentKind10b5-1
- Nov 3, 2026Catherine T. DohertyExecutive Vice PresidentKind10b5-1
- Nov 3, 2026Catherine T. DohertyExecutive Vice PresidentKind10b5-1
- Nov 3, 2026Catherine T. DohertyExecutive Vice PresidentKind10b5-1
- Nov 3, 2026Catherine T. DohertyExecutive Vice PresidentKind10b5-1
- Nov 3, 2026Catherine T. DohertyExecutive Vice PresidentKind10b5-1
- Nov 3, 2026Catherine T. DohertyExecutive Vice PresidentKind10b5-1
- Nov 3, 2026Mark E DelaneySVP & Chief Commercial OfficerKind
- Oct 26, 2026Gary M PfeifferDirectorKind10b5-1
- Oct 21, 2026Robert B CarterDirectorKind
- Oct 21, 2026Sam SamadExecutive Vice President & CFOKind
- Oct 21, 2026Vicky B GreggDirectorKind
- Oct 21, 2026Karthik KuppusamySVP, Clinical SolutionsKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | Michael J DeppeSVP, Corp. Controller & CAO | 10b5-1 | 6,261 | $95.80 | $599.8K | Form 4 |
| Nov 13, 2026 | Michael J DeppeSVP, Corp. Controller & CAO | 10b5-1 | 6,261 | $260.17 | $1.6M | Form 4 |
| Nov 13, 2026 | Michael J DeppeSVP, Corp. Controller & CAO | 10b5-1 | 5,515 | $103.57 | $571.2K | Form 4 |
| Nov 13, 2026 | Michael J DeppeSVP, Corp. Controller & CAO | 10b5-1 | 5,515 | $260.17 | $1.4M | Form 4 |
| Nov 9, 2026 | Patrick PlewmanSVP for Diagnostic Services | 10b5-1 | 4,274 | $127.73 | $545.9K | Form 4 |
| Nov 9, 2026 | Patrick PlewmanSVP for Diagnostic Services | 10b5-1 | 4,274 | $257.34 | $1.1M | Form 4 |
| Nov 9, 2026 | Patrick PlewmanSVP for Diagnostic Services | 10b5-1 | 6,793 | $127.81 | $868.2K | Form 4 |
| Nov 9, 2026 | Patrick PlewmanSVP for Diagnostic Services | 10b5-1 | 6,793 | $257.34 | $1.7M | Form 4 |
| Nov 9, 2026 | Patrick PlewmanSVP for Diagnostic Services | 10b5-1 | 650 | $257.34 | $167.3K | Form 4 |
| Nov 3, 2026 | Subu RamachandranSVP, Regional Businesses | 352 | – | – | Form 4 | |
| Nov 3, 2026 | Catherine T. DohertyExecutive Vice President | 10b5-1 | 4,827 | – | – | Form 4 |
| Nov 3, 2026 | Catherine T. DohertyExecutive Vice President | 10b5-1 | 22.1K | $121.81 | $2.7M | Form 4 |
| Nov 3, 2026 | Catherine T. DohertyExecutive Vice President | 10b5-1 | 3,818 | $245.45 | $937.1K | Form 4 |
| Nov 3, 2026 | Catherine T. DohertyExecutive Vice President | 10b5-1 | 5,990 | $246.26 | $1.5M | Form 4 |
| Nov 3, 2026 | Catherine T. DohertyExecutive Vice President | 10b5-1 | 1,151 | $246.98 | $284.3K | Form 4 |
| Nov 3, 2026 | Catherine T. DohertyExecutive Vice President | 10b5-1 | 2,358 | $248.38 | $585.7K | Form 4 |
| Nov 3, 2026 | Catherine T. DohertyExecutive Vice President | 10b5-1 | 3,004 | $249.40 | $749.2K | Form 4 |
| Nov 3, 2026 | Catherine T. DohertyExecutive Vice President | 10b5-1 | 2,877 | $250.49 | $720.7K | Form 4 |
| Nov 3, 2026 | Catherine T. DohertyExecutive Vice President | 10b5-1 | 2,907 | $251.24 | $730.4K | Form 4 |
| Nov 3, 2026 | Mark E DelaneySVP & Chief Commercial Officer | 2,615 | – | – | Form 4 | |
| Oct 26, 2026 | Gary M PfeifferDirector | 10b5-1 | 1,203 | $243.00 | $292.3K | Form 4 |
| Oct 21, 2026 | Robert B CarterDirector | 10 | $235.93 | $2.4K | Form 4 | |
| Oct 21, 2026 | Sam SamadExecutive Vice President & CFO | 90 | $235.94 | $21.2K | Form 4 | |
| Oct 21, 2026 | Vicky B GreggDirector | 63 | $235.94 | $14.9K | Form 4 | |
| Oct 21, 2026 | Karthik KuppusamySVP, Clinical Solutions | 33 | $235.94 | $7.8K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 2, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by DGX's officers and directors from 2006 up to November 18, 2025, 20 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 15 more, back to 2006
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- BlackRock, Inc.Share of class8.40%
- Vanguard Capital ManagementShare of class7.53%
- Vanguard Portfolio ManagementShare of class5.54%
- State StreetShare of class5.00%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8.40% | 9.31M | Apr 17, 2025 | 13G/A | |
| Vanguard Capital Management | 7.53% | 8.27M | Apr 30, 2026 | 13G | |
| Vanguard Portfolio Management | 5.54% | 6.10M | Apr 29, 2026 | 13G | |
| State Street | 5.00% | 5.56M | Nov 10, 2026 | 13G |
Fell to 5% or less (2)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Citadel Advisors (Griffin)In the quarter+224%
- Millennium Mgmt (Englander)In the quarter×10.3
- Point72 (Cohen)In the quarter
- Bridgewater (Dalio)In the quarter-5.5%
- D.E. ShawIn the quarter+261%
- AQR CapitalIn the quarter+11%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Citadel Advisors (Griffin) | 431.6K | +224% | $101M | 0.06% |
| Millennium Mgmt (Englander) | 117.5K | ×10.3 | $27M | 0.02% |
| Point72 (Cohen) | – | – | 0.01% | |
| Bridgewater (Dalio) | 3,548 | -5.5% | $800.0K | 0.00% |
| D.E. Shaw | 17.4K | +261% | $4.1M | 0.00% |
| AQR Capital | 68.0K | +11% | $16M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 3.25% of its shares outstanding were held short, +4.6% since the report before.
- Shares held short
- 3.57M
- 3.25%
- Since the report before3.42M on Sep 30, 2026
- +4.6%
- 3.4
- 1.06M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 40%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 2.51M
- Nov 15, 2023: Shares held short 2.69M
- Nov 30, 2023: Shares held short 2.27M
- Dec 15, 2023: Shares held short 2.55M
- Dec 29, 2023: Shares held short 2.49M
- Jan 12, 2024: Shares held short 3.04M
- Jan 31, 2024: Shares held short 3.44M
- Feb 15, 2024: Shares held short 2.97M
- Feb 29, 2024: Shares held short 2.75M
- Mar 15, 2024: Shares held short 2.65M
- Mar 28, 2024: Shares held short 2.55M
- Apr 15, 2024: Shares held short 3.02M
- Apr 30, 2024: Shares held short 2.80M
- May 15, 2024: Shares held short 2.70M
- May 31, 2024: Shares held short 2.65M
- Jun 14, 2024: Shares held short 2.36M
- Jun 28, 2024: Shares held short 2.27M
- Jul 15, 2024: Shares held short 2.28M
- Jul 31, 2024: Shares held short 2.33M
- Aug 15, 2024: Shares held short 2.79M
- Aug 30, 2024: Shares held short 2.55M
- Sep 13, 2024: Shares held short 2.42M
- Sep 30, 2024: Shares held short 1.97M
- Oct 15, 2024: Shares held short 2.33M
- Oct 31, 2024: Shares held short 2.38M
- Nov 15, 2024: Shares held short 2.59M
- Nov 29, 2024: Shares held short 2.04M
- Dec 13, 2024: Shares held short 1.91M
- Dec 31, 2024: Shares held short 2.03M
- Jan 15, 2025: Shares held short 2.27M
- Jan 31, 2025: Shares held short 2.58M
- Feb 14, 2025: Shares held short 2.96M
- Feb 28, 2025: Shares held short 2.57M
- Mar 14, 2025: Shares held short 2.76M
- Mar 31, 2025: Shares held short 2.86M
- Apr 15, 2025: Shares held short 3.50M
- Apr 30, 2025: Shares held short 4.01M
- May 15, 2025: Shares held short 3.90M
- May 30, 2025: Shares held short 3.82M
- Jun 13, 2025: Shares held short 3.64M
- Jun 30, 2025: Shares held short 4.98M
- Jul 15, 2025: Shares held short 4.58M
- Jul 31, 2025: Shares held short 4.74M
- Aug 15, 2025: Shares held short 4.03M
- Aug 29, 2025: Shares held short 4.25M
- Sep 15, 2025: Shares held short 4.42M
- Sep 30, 2025: Shares held short 4.33M
- Oct 15, 2025: Shares held short 3.95M
- Oct 31, 2025: Shares held short 4.61M
- Nov 14, 2025: Shares held short 4.29M
- Nov 28, 2025: Shares held short 4.30M
- Dec 15, 2025: Shares held short 4.23M
- Dec 31, 2025: Shares held short 5.85M
- Jan 15, 2026: Shares held short 5.72M
- Jan 30, 2026: Shares held short 5.82M
- Feb 13, 2026: Shares held short 4.77M
- Feb 27, 2026: Shares held short 3.87M
- Mar 13, 2026: Shares held short 3.87M
- Mar 31, 2026: Shares held short 4.17M
- Apr 15, 2026: Shares held short 3.55M
- Apr 30, 2026: Shares held short 3.39M
- May 15, 2026: Shares held short 3.72M
- May 29, 2026: Shares held short 3.43M
- Jun 15, 2026: Shares held short 3.42M
- Jun 30, 2026: Shares held short 3.73M
- Jul 15, 2026: Shares held short 3.51M
- Jul 31, 2026: Shares held short 3.68M
- Aug 14, 2026: Shares held short 3.32M
- Aug 31, 2026: Shares held short 3.45M
- Sep 15, 2026: Shares held short 3.60M
- Sep 30, 2026: Shares held short 3.42M
- Oct 15, 2026: Shares held short 3.57M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading64.4% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 64.4% of the shares in the reported trades were short sales, against 55.5% in the 14 before.
- Last 14 sessionsOct 30, 2026 – Nov 18, 2026
- 64.4%
- The 14 beforeOct 12, 2026 – Oct 29, 2026
- 55.5%
- Change
- +8.9 pts
- Short sales a dayon average, of 344.2K shares
- 221.6K
- More than atof 3,656 US-listed companies, same days
- 91%
- Median of alleight in ten from 34.4% to 63.7%
- 50.3%
- Short sales
- Oct 12, 2026: Short sales 28.7%
- Oct 13, 2026: Short sales 32.5%
- Oct 14, 2026: Short sales 33.9%
- Oct 15, 2026: Short sales 34.5%
- Oct 16, 2026: Short sales 49.3%
- Oct 19, 2026: Short sales 52.3%
- Oct 20, 2026: Short sales 42%
- Oct 21, 2026: Short sales 73.1%
- Oct 22, 2026: Short sales 63.4%
- Oct 23, 2026: Short sales 75.5%
- Oct 26, 2026: Short sales 74.9%
- Oct 27, 2026: Short sales 73.1%
- Oct 28, 2026: Short sales 66%
- Oct 29, 2026: Short sales 72.7%
- Oct 30, 2026: Short sales 82.5%
- Nov 2, 2026: Short sales 78.2%
- Nov 3, 2026: Short sales 72.5%
- Nov 4, 2026: Short sales 55.1%
- Nov 5, 2026: Short sales 70.1%
- Nov 6, 2026: Short sales 77.2%
- Nov 9, 2026: Short sales 64.7%
- Nov 10, 2026: Short sales 63.1%
- Nov 11, 2026: Short sales 60.6%
- Nov 12, 2026: Short sales 57.8%
- Nov 13, 2026: Short sales 58.3%
- Nov 16, 2026: Short sales 66.2%
- Nov 17, 2026: Short sales 43%
- Nov 18, 2026: Short sales 49%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- J. E. DavisCEO and PresidentDirectly122.4K
- Catherine T. DohertyEVP, Regional BusinessesDirectly76.5K
- Michael E PrevoznikSVP & General CounselDirectly44.2K
- Michael J DeppeSVP, Corp. Controller & CAODirectly35.9K
- Sam SamadExecutive Vice President & CFODirectly33.6K
- Gary M PfeifferDirectorDirectly29.8K
- Timothy L MainDirectorDirectly27.5K
- Vicky B GreggDirectorDirectly18.4K
- Karthik KuppusamySVP, Clinical SolutionsDirectly15.7K
- Patrick PlewmanSVP for Diagnostic ServicesDirectly14.7K
- Mark E DelaneySVP & Chief Commercial OfficerDirectly13.0K
- Wright Lassiter IIIDirectorDirectly10.3K
- Robert B CarterDirectorDirectly3,874
- Subu RamachandranSVP, Regional BusinessesDirectly2,832
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| J. E. DavisCEO and President | 122.4K | – | Sep 1, 2026 | Form 4 |
| Catherine T. DohertyEVP, Regional Businesses | 76.5K | – | Nov 3, 2026 | Form 4 |
| Michael E PrevoznikSVP & General Counsel | 44.2K | – | Aug 28, 2026 | Form 4 |
| Michael J DeppeSVP, Corp. Controller & CAO | 35.9K | – | Nov 13, 2026 | Form 4 |
| Sam SamadExecutive Vice President & CFO | 33.6K | – | Oct 21, 2026 | Form 4 |
| Gary M PfeifferDirector | 29.8K | – | Oct 26, 2026 | Form 4 |
| Timothy L MainDirector | 27.5K | – | Oct 21, 2026 | Form 4 |
| Vicky B GreggDirector | 18.4K | – | Oct 21, 2026 | Form 4 |
| Karthik KuppusamySVP, Clinical Solutions | 15.7K | – | Oct 21, 2026 | Form 4 |
| Patrick PlewmanSVP for Diagnostic Services | 14.7K | – | Nov 9, 2026 | Form 4 |
| Mark E DelaneySVP & Chief Commercial Officer | 13.0K | – | Nov 3, 2026 | Form 4 |
| Wright Lassiter IIIDirector | 10.3K | – | Oct 21, 2026 | Form 4 |
| Robert B CarterDirector | 3,874 | – | Oct 21, 2026 | Form 4 |
| Subu RamachandranSVP, Regional Businesses | 2,832 | – | Nov 3, 2026 | Form 4 |
A lower bound: it counts only the 14 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
10b5-1 trading plans
Since 2023 every 10-Q and 10-K says which insiders adopted or ended a trading plan (Rule 10b5-1) in the quarter: when, for how many shares, until when. A plan explains the sales that follow months before they show up on Form 4.
- Karthik KuppusamySVP, Clinical SolutionsWhat happenedAdoptedAug 26, 2026Shares1,000
- Michael J. DeppeSVP, Corporate Controller and Chief Accounting OfficerWhat happenedAdoptedAug 13, 2026Shares11.8K
- Patrick PlewmanSVP, Diagnostic ServicesWhat happenedAdoptedAug 11, 2026Shares40.6K
- James E. DavisChairman, Chief Executive Officer and PresidentWhat happenedAdoptedAug 10, 2026Shares172.1K
- Cathy DohertyEVPWhat happenedAdoptedAug 3, 2026Shares34.3K
- Gary PfeifferDirectorWhat happenedAdoptedMay 29, 2026Shares1,203
- Mike PrevoznikSVP, General CounselWhat happenedAdoptedMay 29, 2026Shares32.0K
- Mark DelaneySVP, Chief Commercial OfficerWhat happenedAdoptedApr 23, 2026Shares1,600
- Karthik KuppusamySVP, Clinical SolutionsWhat happenedAdoptedFeb 26, 2026Shares8,147
- Cathy DohertyEVP, Regional BusinessesWhat happenedAdoptedNov 14, 2025Shares37.4K
| Person | What happened | Until | Shares | Filing |
|---|---|---|---|---|
| Karthik KuppusamySVP, Clinical Solutions | AdoptedAug 26, 2026 | Apr 30, 2027 | 1,000 | 10-Q |
| Michael J. DeppeSVP, Corporate Controller and Chief Accounting Officer | AdoptedAug 13, 2026 | Aug 13, 2027 | 11.8K | 10-Q |
| Patrick PlewmanSVP, Diagnostic Services | AdoptedAug 11, 2026 | Mar 31, 2027 | 40.6K | 10-Q |
| James E. DavisChairman, Chief Executive Officer and President | AdoptedAug 10, 2026 | Dec 31, 2027 | 172.1K | 10-Q |
| Cathy DohertyEVP | AdoptedAug 3, 2026 | Apr 30, 2027 | 34.3K | 10-Q |
| Gary PfeifferDirector | AdoptedMay 29, 2026 | May 28, 2027 | 1,203 | 10-Q |
| Mike PrevoznikSVP, General Counsel | AdoptedMay 29, 2026 | Mar 31, 2027 | 32.0K | 10-Q |
| Mark DelaneySVP, Chief Commercial Officer | AdoptedApr 23, 2026 | Jan 22, 2027 | 1,600 | 10-Q |
| Karthik KuppusamySVP, Clinical Solutions | AdoptedFeb 26, 2026 | Feb 26, 2027 | 8,147 | 10-Q |
| Cathy DohertyEVP, Regional Businesses | AdoptedNov 14, 2025 | May 8, 2026 | 37.4K | 10-K |
As the company states them in Item 9B of the 10-K and Part II, Item 5 of the 10-Q, with structured data. A plan allows sales on preset dates and prices. It does not say whether all of them will be executed.
Executive pay
From the Pay versus Performance table every company puts in its proxy statement since 2023: what the chief executive was paid, what was actually paid once the shares vest at year-end values, and how the stock did against the peer group the company itself picked.
$15M
Actually paid: $27M
$3.3M
Actually paid: $5.2M
$161
Peers: $148
Adjusted Diluted Earnings Per Share
From the proxy statement (DEF 14A) of Apr 6, 2026, as filed with the SEC with structured data. Pay in dollars. The company picks its own peer group and measure. DEF 14A
Share repurchases
How many of its own shares the company bought each quarter, at what average price, for how much, and what remains of the program its board authorized, from the table it puts in every 10-Q and 10-K.
- Dec 31, 202510-KAmount$302M
- Sep 30, 202510-QAmount$151M
- Dec 31, 202410-KAmount$150M
- Dec 31, 202310-KAmount$276M
- Dec 31, 202210-KAmount$435M
- Sep 30, 202210-QAmount$400M
- Jun 30, 202210-QAmount$200M
- Mar 31, 202210-QAmount$378M
| Quarter | Shares | Average price | Amount | Left in the program | Filing |
|---|---|---|---|---|---|
| Dec 31, 202510-K | 1.65M | $183.21 | $302M | $436M | 10-K |
| Sep 30, 202510-Q | 857.7K | $176.07 | $151M | $736M | 10-Q |
| Dec 31, 202410-K | 944.1K | $159.00 | $150M | $886M | 10-K |
| Dec 31, 202310-K | 2.03M | $135.95 | $276M | $1.0B | 10-K |
| Dec 31, 202210-K | 2.94M | $147.90 | $435M | $311M | 10-K |
| Sep 30, 202210-Q | 3.09M | $129.68 | $400M | $746M | 10-Q |
| Jun 30, 202210-Q | 1.47M | $136.01 | $200M | $1.1B | 10-Q |
| Mar 31, 202210-Q | 2.79M | $135.35 | $378M | $1.3B | 10-Q |
From the "Issuer Purchases of Equity Securities" table of the 10-Qs and 10-Ks, read without a model. Only the quarters whose shares times average price agree with the cash the company says it paid for repurchases in its cash-flow statement are shown. The shares include those withheld for officers' taxes. A quarter with an accelerated repurchase shows the table's shares and the cash paid, without an average price. 12 filing(s) not shown, as the table was not read or did not agree with the cash.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IHFiShares U.S. Healthcare Providers ETFWeight in the fund3.50%
- QLTYGMO U.S. Quality ETFWeight in the fund1.01%
- SPLVInvesco S&P 500 Low Volatility ETFWeight in the fund0.86%
- COWZPacer US Cash Cows 100 ETFWeight in the fund0.46%
- FVDFirst Trust Value Line Dividend Index FundWeight in the fund0.43%
- IYHiShares U.S. Healthcare ETFWeight in the fund0.42%
- XLVState Street(R) Health Care Select Sector SPDR(R) ETFWeight in the fund0.41%
- VOEVanguard Mid-Cap Value Index FundWeight in the fund0.40%
- VHTVanguard Health Care Index FundWeight in the fund0.37%
- IXJiShares Global Healthcare ETFWeight in the fund0.30%
50 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 1,008
- Q4 2025: Managers 1,050
- Q1 2026: Managers 1,074
- Q2 2026: Managers 1,107
Institutional investors by quarter
The fund managers holding DGX, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 1,107 managers held 105M shares, worth $22.2B. During the quarter 117 opened a position, 84 closed one, 420 added and 349 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+1.1%
- Vanguard Capital ManagementIn the quarter+1.2%
- Vanguard Portfolio ManagementIn the quarter+0.8%
- State StreetIn the quarter+2.5%
- Price T Rowe AssociatesIn the quarter-14%
- Boston PartnersIn the quarter+18%
- JPMorgan ChaseIn the quarter-8.5%
- Geode Capital ManagementIn the quarter+1.7%
- Morgan StanleyIn the quarter-0.8%
- EdgePoint Investment GroupIn the quarter+0.2%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 9.28M | +1.1% | $2.0B |
| Vanguard Capital Management | 7.23M | +1.2% | $1.5B |
| Vanguard Portfolio Management | 6.13M | +0.8% | $1.3B |
| State Street | 5.52M | +2.5% | $1.2B |
| Price T Rowe Associates | 5.44M | -14% | $1.2B |
| Boston Partners | 4.74M | +18% | $1.0B |
| JPMorgan Chase | 3.52M | -8.5% | $749M |
| Geode Capital Management | 3.14M | +1.7% | $663M |
| Morgan Stanley | 2.46M | -0.8% | $522M |
| EdgePoint Investment Group | 2.25M | +0.2% | $476M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
The full analysis
What do Quest Diagnostics's filings show?
Who buys and sells is one part of Quest Diagnostics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have DGX's insiders bought or sold?
From Jun 2, 2026 to Nov 16, 2026 Quest Diagnostics's insiders bought 0 and sold $24M of shares on the market. 100% of the sales were under set 10b5-1 plans.
Which well-known managers hold DGX?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $101M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.